Global Pharmatech Incの収益品質スコアはB+/52.836895です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Global Pharmatech Incはいつ収益を報告しますか?
Global Pharmatech Incの次の収益報告はに予定されています
Global Pharmatech Incの予想収益はいくらですか?
ウォール街のアナリストによると、Global Pharmatech Incの予想収益は$です。
Global Pharmatech Incは収益予想を上回りましたか?
Global Pharmatech Incの最近の収益は$で、予想を。
主要データ
前終値
$0.05
始値
$0.05
当日レンジ
$0.05 - $0.05
52週レンジ
$0.05 - $0.242
取引高
2.1K
平均取引高
35
配当利回り
--
1株当たり利益(TTM)
-0.10
時価総額
$20.7M
GBLPとは何ですか?
Global Pharmatech, Inc. engages in the discovery, development, manufacturing, and marketing of proprietary drugs developed based on traditional Chinese medicine. The company is headquartered in Changchun, Jilin and currently employs 217 full-time employees. The company went IPO on 2006-05-12. The Company’s main patented products include JUTAI SOFT CAPSULE, QINGXUAN ANTI-HYPERTENSION TABLET, YANREQING TABLET. The firm is also engaged in the manufacture and sales of other proprietary drugs, generics and dietary supplements used to treat symptoms ranging from headaches, coughing and dry mouth to infections and numbness of limbs. The firm also engages in the provision of biotechnology services, including research and development, testing, manufacturing drugs in liquid and solid dose forms, sales and marketing. The firm conducts its business in the domestic and overseas markets.